Compass Therapeutics (CMPX) Competitors $1.38 +0.01 (+0.73%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CMPX vs. AVXL, IMNM, KURA, KROS, TYRA, CRON, ERAS, EOLS, DNTH, and RAPPShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Anavex Life Sciences (AVXL), Immunome (IMNM), Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Cronos Group (CRON), Erasca (ERAS), Evolus (EOLS), Dianthus Therapeutics (DNTH), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. Compass Therapeutics vs. Anavex Life Sciences Immunome Kura Oncology Keros Therapeutics Tyra Biosciences Cronos Group Erasca Evolus Dianthus Therapeutics Rapport Therapeutics Compass Therapeutics (NASDAQ:CMPX) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability. Does the MarketBeat Community favor CMPX or AVXL? Anavex Life Sciences received 401 more outperform votes than Compass Therapeutics when rated by MarketBeat users. Likewise, 74.44% of users gave Anavex Life Sciences an outperform vote while only 73.17% of users gave Compass Therapeutics an outperform vote. CompanyUnderperformOutperformCompass TherapeuticsOutperform Votes3073.17% Underperform Votes1126.83% Anavex Life SciencesOutperform Votes43174.44% Underperform Votes14825.56% Which has preferable valuation and earnings, CMPX or AVXL? Compass Therapeutics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass Therapeutics$850K223.38-$42.49M-$0.37-3.73Anavex Life SciencesN/AN/A-$47.51M-$0.50-17.26 Is CMPX or AVXL more profitable? Anavex Life Sciences' return on equity of -30.64% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -32.37% -30.67% Anavex Life Sciences N/A -30.64%-28.23% Does the media favor CMPX or AVXL? In the previous week, Anavex Life Sciences had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 3 mentions for Anavex Life Sciences and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.92 beat Anavex Life Sciences' score of 0.75 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Anavex Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in CMPX or AVXL? 68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are owned by institutional investors. 28.5% of Compass Therapeutics shares are owned by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, CMPX or AVXL? Compass Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Do analysts recommend CMPX or AVXL? Compass Therapeutics presently has a consensus target price of $6.75, suggesting a potential upside of 389.13%. Anavex Life Sciences has a consensus target price of $43.00, suggesting a potential upside of 398.26%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Compass Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryCompass Therapeutics beats Anavex Life Sciences on 9 of the 17 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$189.87M$2.94B$5.07B$9.08BDividend YieldN/A1.90%4.87%4.21%P/E Ratio-3.7345.9499.0517.15Price / Sales223.38411.851,121.17116.80Price / CashN/A182.1041.5237.88Price / Book1.183.894.754.78Net Income-$42.49M-$42.21M$119.33M$225.60M7 Day Performance-5.48%-2.14%-1.86%-1.23%1 Month PerformanceN/A4.21%11.40%3.07%1 Year Performance-15.34%18.39%30.26%16.48% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics2.6637 of 5 stars$1.38+0.7%$6.75+389.1%-13.2%$189.87M$850,000.00-3.7320AVXLAnavex Life Sciences3.3451 of 5 stars$9.33+10.3%$43.00+360.9%-2.5%$791.18MN/A-18.3640IMNMImmunome2.566 of 5 stars$12.44-1.1%$28.83+131.8%+33.0%$776.47M$10.13M-1.5540Positive NewsKURAKura Oncology4.4837 of 5 stars$9.89+2.7%$29.38+197.0%-27.0%$769.05MN/A-4.08142KROSKeros Therapeutics3.2961 of 5 stars$18.73-0.5%$81.33+334.2%-49.6%$758.70M$651,000.00-3.61100High Trading VolumeTYRATyra Biosciences2.0741 of 5 stars$14.99+0.3%$31.00+106.8%+2.0%$758.49MN/A-9.2820Positive NewsCRONCronos Group1.8449 of 5 stars$1.94+0.3%$3.00+55.0%+4.8%$739.75M$87.24M-15.19356News CoverageERASErasca2.17 of 5 stars$2.60+1.6%$5.90+126.9%+35.8%$735.09MN/A-3.08126News CoveragePositive NewsGap UpEOLSEvolus3.8301 of 5 stars$11.53+0.2%$23.00+99.5%+12.5%$730.08M$202.09M-12.73170DNTHDianthus Therapeutics1.3413 of 5 stars$24.21+1.7%$46.43+91.8%+213.2%$716.62M$2.83M-9.5280Analyst ForecastNews CoverageRAPPRapport Therapeutics1.5264 of 5 stars$19.38+3.2%$35.00+80.6%N/A$708.92MN/A0.00N/A Related Companies and Tools Related Companies AVXL Alternatives IMNM Alternatives KURA Alternatives KROS Alternatives TYRA Alternatives CRON Alternatives ERAS Alternatives EOLS Alternatives DNTH Alternatives RAPP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMPX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPX Stock Alerts